NASDAQ:EQ - Equillium Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 142.21 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$5.78
▼ -0.96 (-14.24%)
1 month | 3 months | 12 months
Get New Equillium Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EQ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EQ

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$14.00
▲ +142.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Equillium in the last 3 months. The average price target is $14.00, with a high forecast of $16.00 and a low forecast of $12.00. The average price target represents a 142.21% upside from the last price of $5.78.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Equillium. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/1/2021SVB LeerinkReiterated RatingBuyLow
i
3/9/2021JonestradingInitiated CoverageBuy$14.00High
i
3/3/2021JonestradingInitiated CoverageBuy$14.00Medium
i
2/9/2021HC WainwrightReiterated RatingBuy$12.00Low
i
11/30/2020HC WainwrightLower Price TargetBuy$22.00 ➝ $12.00High
i
11/30/2020HC WainwrightReiterated RatingHold ➝ Buy$22.00 ➝ $12.00High
i
9/21/2020HC WainwrightReiterated RatingBuy$22.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/21/2020HC WainwrightLower Price TargetBuy$24.00 ➝ $22.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/13/2020Jefferies Financial GroupReiterated RatingBuy$16.00Low
i
8/10/2020Stifel NicolausReiterated RatingBuy$14.00High
i
7/13/2020HC WainwrightReiterated RatingBuy$14.00 ➝ $24.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/13/2020Stifel NicolausReiterated RatingBuy$22.00 ➝ $10.00High
i
5/26/2020HC WainwrightReiterated RatingBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/19/2020HC WainwrightReiterated RatingBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/27/2020HC WainwrightReiterated RatingBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/2/2020SVB LeerinkReiterated RatingOutperformLow
i
Rating by T. Smith at SVB Leerink LLC
12/30/2019HC WainwrightReiterated RatingBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/13/2019HC WainwrightReiterated RatingBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/12/2019HC WainwrightInitiated CoverageBuy$14.00Low
i
Rating by R. Selvaraju at HC Wainwright
7/2/2019HC WainwrightInitiated CoverageBuy$14.00High
i
Rating by R. Selvaraju at HC Wainwright
2/22/2019SVB LeerinkReiterated RatingOutperform$16.00Medium
i
Rating by P. Sarraf at SVB Leerink LLC
11/6/2018Jefferies Financial GroupInitiated CoverageBuy$19.00High
i
11/6/2018Stifel NicolausInitiated CoverageBuy$22.00High
i
(Data available from 4/21/2016 forward)
Equillium logo
Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $5.78
$5.78
$6.73

50 Day Range

MA: $7.20
$6.55
$8.30

52 Week Range

Now: $5.78
$2.37
$27.05

Volume

240,412 shs

Average Volume

427,800 shs

Market Capitalization

$167.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Equillium?

The following sell-side analysts have issued reports on Equillium in the last twelve months: HC Wainwright, Jefferies Financial Group Inc., Jonestrading, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for EQ.

What is the current price target for Equillium?

4 Wall Street analysts have set twelve-month price targets for Equillium in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 142.2%. Jefferies Financial Group Inc. has the highest price target set, predicting EQ will reach $16.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for Equillium in the next year.
View the latest price targets for EQ.

What is the current consensus analyst rating for Equillium?

Equillium currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EQ will outperform the market and that investors should add to their positions of Equillium.
View the latest ratings for EQ.

What other companies compete with Equillium?

How do I contact Equillium's investor relations team?

Equillium's physical mailing address is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. The company's listed phone number is 858 412 5302 and its investor relations email address is [email protected] The official website for Equillium is equilliumbio.com.